Media stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 45.9156131066614 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several analysts have issued reports on the stock. ValuEngine upgraded shares of Cumberland Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. B. Riley started coverage on shares of Cumberland Pharmaceuticals in a research report on Tuesday, April 17th. They set a “buy” rating and a $9.25 price target for the company.
Shares of Cumberland Pharmaceuticals traded up $0.09, hitting $5.90, during midday trading on Friday, Marketbeat.com reports. 2,734 shares of the stock traded hands, compared to its average volume of 8,322. The company has a market cap of $91.28 million, a price-to-earnings ratio of -84.29 and a beta of 0.65. The company has a current ratio of 4.10, a quick ratio of 3.70 and a debt-to-equity ratio of 0.20. Cumberland Pharmaceuticals has a one year low of $5.51 and a one year high of $7.96.
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.
Featured Article: Growth Stocks
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.